Opus Genetics Named Biotech Innovator for 7 AAV Gene Therapies
Opus Genetics was named to a leading business magazine’s 2026 Most Innovative Companies list in the Biotech category, among 720 honorees across 59 sectors. Its pipeline features seven AAV-based gene therapies, including OPGx-LCA5 and OPGx-BEST1, and a Phase 3 small-molecule ophthalmic solution candidate.
1. Award Recognition
Opus Genetics was selected for a leading business magazine’s 2026 Most Innovative Companies list in the Biotech category, one of 720 honorees across 59 sectors and regions, highlighting its role in driving industry progress.
2. Pipeline Highlights
The company’s program portfolio includes seven AAV-based gene therapies led by OPGx-LCA5 for LCA5 mutations and OPGx-BEST1 for BEST1-related degeneration, alongside a small-molecule Phentolamine Ophthalmic Solution 0.75% progressing in a Phase 3 pivotal trial.
3. Patient-Centered Development
Opus Genetics employs a novel, patient-focused approach by partnering directly with individuals to define meaningful clinical outcomes that extend beyond traditional endpoints in inherited retinal disease trials.